ONCS - オンコセク・メディカル (OncoSec Medical Incorporated)

ONCSのニュース

   OncoSec Aims to Treat Cancer with what the Body Makes Naturally — IL-12  2021/05/03 14:24:39 Benzinga
There’s no arguing that immunotherapies and immune checkpoint inhibitors have drastically improved cancer patients’ chances for survival. Checkpoint inhibitors are the most widely used immunotherapy and work by amplifying the immune system’s ability to fight cancer, with some remarkable success. However, the biotech company OncoSec (NASDAQ: ONCS ) believes that the power of immunotherapies has yet to be fully realized. Checkpoint inhibitors are intended to “block the off-switch” to the body’s T-cells to allow such cells to destroy cancers. Although it seems they’re most effective in “hot” or T-cell inflamed tumors, which have already been identified by the immune system as a target, as opposed to “cold” or immunologically devoid tumors that have not provoked an immune response. Here’s where OncoSec’s DNA gene transfer technology, TAVO™ (tavokinogene telseplasmid), comes in. “TAVO takes cold tumors, turns them hot and leverages drugs like Keytruda that allow T-cells to uncover and attack tumor cells.
   OncoSec Medical Earnings Report: Here’s what to expect from Stock market Insights & financial analysis  2021/03/11 14:02:00 Stock Market Daily
OncoSec Medical announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   OncoSec Announces Approval of $2.5 Million in NJEDA NOL Program Tax Benefits  2021/02/23 14:00:00 PR Newswire
PENNINGTON, N.J. and SAN DIEGO, Feb. 23, 2021 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (Nasdaq:ONCS), a late-stage biotechnology company focused on designing, developing and commercializing innovative therapies and proprietary medical approaches to stimulate and to guide…
   OncoSec Appoints Bridget O'Keeffe, Ph.D. as Vice President of Clinical Development  2021/02/18 13:30:00 PR Newswire
PENNINGTON, N.J. and SAN DIEGO, Feb. 18, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced the appointment of Bridget O'Keeffe, Ph.D., a biotech industry veteran with more than 15 years of experience, as Vice President of Clinical…
   OncoSec Announces First Subjects Dosed in Phase 1 Trial of CORVax12, OncoSec's COVID-19 Vaccine Candidate Combining Interleukin-12 (IL-12) with an Enhanced SARS-CoV-2 Spike Protein  2021/01/27 14:00:00 PR Newswire
PENNINGTON, N.J. and SAN DIEGO, Jan. 27, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) today announced that it has dosed several subjects in its Phase 1 clinical trial of CORVax12, the only vaccine candidate to include an immunostimulatory cytokine to address COVID-19….
   OncoSec Medical Earnings Report: Here’s what to expect from Stock market Insights & financial analysis  2021/03/11 14:02:00 Stock Market Daily
OncoSec Medical announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   OncoSec Announces Approval of $2.5 Million in NJEDA NOL Program Tax Benefits  2021/02/23 14:00:00 PR Newswire
PENNINGTON, N.J. and SAN DIEGO, Feb. 23, 2021 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (Nasdaq:ONCS), a late-stage biotechnology company focused on designing, developing and commercializing innovative therapies and proprietary medical approaches to stimulate and to guide…
   OncoSec Appoints Bridget O'Keeffe, Ph.D. as Vice President of Clinical Development  2021/02/18 13:30:00 PR Newswire
PENNINGTON, N.J. and SAN DIEGO, Feb. 18, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced the appointment of Bridget O'Keeffe, Ph.D., a biotech industry veteran with more than 15 years of experience, as Vice President of Clinical…
   OncoSec Announces First Subjects Dosed in Phase 1 Trial of CORVax12, OncoSec's COVID-19 Vaccine Candidate Combining Interleukin-12 (IL-12) with an Enhanced SARS-CoV-2 Spike Protein  2021/01/27 14:00:00 PR Newswire
PENNINGTON, N.J. and SAN DIEGO, Jan. 27, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) today announced that it has dosed several subjects in its Phase 1 clinical trial of CORVax12, the only vaccine candidate to include an immunostimulatory cytokine to address COVID-19….
   OncoSec Medical Closes $42.0 Million Public Offering of Common Stock  2021/01/25 21:00:00 PR Newswire
PENNINGTON, N.J. and SAN DIEGO, Jan. 25, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a late-stage biotechnology company focused on designing, developing and commercializing innovative therapies and proprietary medical approaches to…
   OncoSec Medical Earnings Report: Here’s what to expect from Stock market Insights & financial analysis  2021/03/11 14:02:00 Stock Market Daily
OncoSec Medical announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   OncoSec Announces Approval of $2.5 Million in NJEDA NOL Program Tax Benefits  2021/02/23 14:00:00 PR Newswire
PENNINGTON, N.J. and SAN DIEGO, Feb. 23, 2021 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (Nasdaq:ONCS), a late-stage biotechnology company focused on designing, developing and commercializing innovative therapies and proprietary medical approaches to stimulate and to guide…
   OncoSec Appoints Bridget O'Keeffe, Ph.D. as Vice President of Clinical Development  2021/02/18 13:30:00 PR Newswire
PENNINGTON, N.J. and SAN DIEGO, Feb. 18, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced the appointment of Bridget O'Keeffe, Ph.D., a biotech industry veteran with more than 15 years of experience, as Vice President of Clinical…
   OncoSec Announces First Subjects Dosed in Phase 1 Trial of CORVax12, OncoSec's COVID-19 Vaccine Candidate Combining Interleukin-12 (IL-12) with an Enhanced SARS-CoV-2 Spike Protein  2021/01/27 14:00:00 PR Newswire
PENNINGTON, N.J. and SAN DIEGO, Jan. 27, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) today announced that it has dosed several subjects in its Phase 1 clinical trial of CORVax12, the only vaccine candidate to include an immunostimulatory cytokine to address COVID-19….
   OncoSec Medical Closes $42.0 Million Public Offering of Common Stock  2021/01/25 21:00:00 PR Newswire
PENNINGTON, N.J. and SAN DIEGO, Jan. 25, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a late-stage biotechnology company focused on designing, developing and commercializing innovative therapies and proprietary medical approaches to…

calendar